UCSF

ZINC39716195

Substance Information

In ZINC since Heavy atoms Benign functionality
March 5th, 2010 27 Yes

Download: MOL2 SDF SMILES Flexibase

Physical Representations

Type pH range xlogP Des A‑Pol Apolar desolvation (kcal/mol) Des Pol Polar desolvation (kcal/mol) H Don H-bond donors H Acc H-bond acceptors Chg Net charge tPSA (Ų) MWT Molecular weight (g/mol) RB Rotatable bonds DL
Ref Reference (pH 7) 2.17 5.71 -10.66 3 7 0 103 363.376 2
Mid Mid (pH 6-8) 2.17 7.14 -14.15 2 7 0 100 362.368 2
Mid Mid (pH 6-8) 2.17 6.19 -38.53 3 7 0 103 363.376 2
Mid Mid (pH 6-8) 2.17 7.14 -11.29 2 7 0 100 362.368 2
Mid Mid (pH 6-8) 2.17 6.09 -44.34 3 7 0 103 363.376 2
Lo Low (pH 4.5-6) 1.99 7.08 -12.23 4 7 0 101 364.384 3
Lo Low (pH 4.5-6) 2.17 5.81 -50.7 3 7 0 103 363.376 2

Vendor Notes

Note Type Comments Provided By
ALOGPS_SOLUBILITY 2.11e-02 g/l DrugBank-experimental

Activity (Go SEA)

Clustered Target Annotations
Code Description Organism Class Affinity (nM) LE (kcal/mol/atom) Type
TGFR1-1-E TGF-beta Receptor Type I (cluster #1 Of 1), Eukaryotic Eukaryotes 7 0.42 Binding ≤ 10μM
ChEMBL Target Annotations
Uniprot Swissprot Description Affinity (nM) LE (kcal/mol/atom) Type
TGFR1_HUMAN P36897 TGF-beta Receptor Type I, Human 180 0.35 Binding ≤ 1μM
TGFR1_HUMAN P36897 TGF-beta Receptor Type I, Human 180 0.35 Binding ≤ 10μM

Reactome Annotations from Targets (via Uniprot)

Description Species
Downregulation of TGF-beta receptor signaling
SMAD2/3 MH2 Domain Mutants in Cancer
SMAD2/3 Phosphorylation Motif Mutants in Cancer
TGF-beta receptor signaling activates SMADs
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
TGFBR1 KD Mutants in Cancer
TGFBR1 LBD Mutants in Cancer
TGFBR2 Kinase Domain Mutants in Cancer

Analogs ( Draw Identity 99% 90% 80% 70% )

No pre-computed analogs available. Try a structural similarity search.